Acadia Pharmaceuticals Announces FDA Approval of Daybue Stix (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Dec 15, 2025 - 06:00
 0  2
SAN DIEGO—(BUSINESS WIRE)—Dec. 12, 2025—Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved Daybue Stix (trofinetide) for oral solution, a dye- and...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0